Tech Company Financing Transactions
OriGene Technologies Funding Round
Morningside Group, private investors and Zero2IPO participated in a $16 million Series B funding round for OriGene Technologies. The round was announced on 3/18/2010.
Transaction Overview
Company Name
Announced On
3/18/2010
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series B
Investors
Proceeds Purpose
The proceeds from the funding will be used to continue to build OriGene's TrueMAB� monoclonal antibody collection.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9620 Medical Center Dr. 200
Rockville, MD 20850
USA
Rockville, MD 20850
USA
Phone
Website
Email Address
Overview
OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wei He
Browse more venture capital transactions:
Prev: 3/18/2010: Smartling venture capital transaction
Next: 3/19/2010: Aureon Biosciences venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs